Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Devonian Health Group, Inc. (TSE:GSD)
TSXV:GSD
Devonian Health Group, Inc. (GSD) Stock Price & Analysis
4 Followers
GSD Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.10 - C$0.28
Previous CloseC$0.2
Volume2.00
Average Volume (3M)13.86K
Market Cap
C$29.05M
Enterprise ValueC$28.20M
Total Cash (Recent Filing)C$1.00M
Total Debt (Recent Filing)C$150.87K
Price to Earnings (P/E)N/A
Beta0.40
Next Earnings
Jun 26, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding148,222,531
10 Day Avg. Volume405
30 Day Avg. Volume13,864
Standard Deviation0.30
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)9.64
Price to Sales (P/S)27.55
Price to Cash Flow (P/CF)-21.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Devonian Health Group, Inc. News
PremiumCompany Announcements
Devonian Health Group’s Strong Q2 Performance
PremiumCompany Announcements
Devonian Health Group Secures Fresh Capital
PremiumCompany Announcements
Devonian Health Welcomes New Board ExpertisePremiumCompany Announcements
Devonian Subsidiary Introduces GERD Generic in CanadaOptions Prices
Currently, No data available
---
Ownership Overview
24.74% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
75.26% Public Companies and
Individual Investors
GSD FAQ
What was Devonian Health Group, Inc.’s price range in the past 12 months?
Devonian Health Group, Inc. lowest stock price was C$0.10 and its highest was C$0.28 in the past 12 months.
What is Devonian Health Group, Inc.’s market cap?
Currently, no data Available
When is Devonian Health Group, Inc.’s upcoming earnings report date?
Devonian Health Group, Inc.’s upcoming earnings report date is Jun 26, 2024 which is in 40 days.
How were Devonian Health Group, Inc.’s earnings last quarter?
Devonian Health Group, Inc. released its earnings results on Mar 28, 2024. The company reported -C$0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.008.
Is Devonian Health Group, Inc. overvalued?
According to Wall Street analysts Devonian Health Group, Inc.’s price is currently Overvalued.
Does Devonian Health Group, Inc. pay dividends?
Devonian Health Group, Inc. does not currently pay dividends.
What is Devonian Health Group, Inc.’s EPS estimate?
Devonian Health Group, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Devonian Health Group, Inc. have?
Devonian Health Group, Inc. has 146,730,530 shares outstanding.
What happened to Devonian Health Group, Inc.’s price movement after its last earnings report?
Devonian Health Group, Inc. reported an EPS of -C$0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Devonian Health Group, Inc.?
Currently, no hedge funds are holding shares in TSE:GSD
---
Devonian Health Group, Inc. Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Company Description
Devonian Health Group, Inc.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It is intended to develop prescription botanical drugs which could be from plant materials, algae, macroscopic fungi, and combinations thereof. The company's technology platform, The Supra Molecular Complex Extraction, and Stabilization Technology provide a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. The products of the group include botanical pharmaceuticals, Thykamine; and derma-cosmeceutical product, Purgenesis.
---
Technical Analysis
---